Drug Trial Radar · NCT01578239
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Last checked: Nov 19, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Sep 6, 2012
Primary completion
Jul 31, 2015
Study completion Jan 18, 2021
Sponsor
- Lead sponsor
- Advanced Accelerator ApplicationsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours with progression despite LAR treatment.
Conditions
- Carcinoid Tumor of the Small Bowel
- Neuroendocrine Tumour
Interventions
Octreotide LARDrug
In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died. In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
177Lu-DOTA0-Tyr3-OctreotateDrug
Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached on 24July2015, assessed up to approximately 34 months
Locations
39 sites in 8 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center Samuel Oschin Cancer Center
Los Angeles, California
Stanford Cancer Center
Palo Alto, California
Moffitt Cancer Center
Tampa, Florida
Northwestern Medical Faculty Foundation
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Duke University Medical Center
Durham, North Carolina
Kettering Medical Center
Kettering, Ohio
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Henry-Joyce Cancer Clinic
Nashville, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas
Digestive Oncology, Leuven Cancer Institute
Leuven, Brabant Flamand, Belgium
Hôpital Beaujon AP-HP
Clichy, France
Centre Hospitalier Lyon-Sud
Lyon, Auvergne-Rhône-Alpes, France
Institut Gustave Roussy
Villejuif, Île-de-France Region, France
Institut Claudius Regaud
Toulouse, Midi-Pyrénées, France
Hotel Dieu/CHU Nantes
Nantes, Pays de la Loire Region, France
Hôpital la Timone /CHU Marseille
Marseille, Provence-Alpes-Côte d'Azur Region, France
Charité, Virchow-Klinikum, Gastroentrology, Hepatology & Endocrinology
Berlin, Germany
Klinikum Rechts Isar, Nuclear Medicine
Munich, Bavaria, Germany
Universitätsmedizin Mainz, Medizinische Klinik I Schwerpunkt Endokrinologie
Mainz, Rhineland-Palatinate, Germany
Zentralklinik Bad Berka
Bad Berka, Thuringia, Germany
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Università "Sapienza" di Roma, Facoltà di Medicina e Psicologia, Ospedale S. Andrea-Roma
Roma, Italy
Istituto Oncologico Romagnolo per lo Studio dei Tumori
Meldola, Emilia-Romagna, Italy
IEO Istituto Europeo di Oncologia
Milan, Lombardy, Italy
Presidio Osp. Di Macerata
Province of Macerata, The Marches, Italy
Azienda Ospedaliero - Universitaria Pisana (Presidio Ospedaliero S. Chiara)
Pisa, Tuscany, Italy
Centro Hospitalar e Universitario de Coimbra
Coimbra, Centro, Portugal
Instituto Português de Oncologia
Porto, Norte, Portugal
Ramon y Cajal University Hospital
Madrid, Spain
University Hospital of Bellvitge
Hospitalet de Llobregat (Barcelona), Catalonia, Spain
Beatson Oncology Centre
Glasgow, United Kingdom
Royal Free Hospital
London, United Kingdom
Imperial College Healthcare Trust, Hammersmith Hospital
London, United Kingdom
The Christie NHS foundation Trust
Manchester, United Kingdom
University of Oxford
Oxford, South East England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.